Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma
CONCLUSION: The addition of dasatinib did not appear to add incremental clinical benefit to FOLFOX in untreated mPC patients.PMID:34101295 | DOI:10.1002/onco.13853
Source: The Oncologist - Category: Cancer & Oncology Authors: Thomas J George Azka Ali Yu Wang Ji-Hyun Lee Alison M Ivey David DeRemer Karen C Daily Carmen J Allegra Steven J Hughes Z Hugh Fan Miles E Cameron Andrew R Judge Jose G Trevino Source Type: research
More News: Adenocarcinoma | Allegra | Cancer | Cancer & Oncology | Eloxatin | History of Medicine | Lessons | Oral Cancer | Pancreas | Pancreatic Cancer | Study